AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
med-marvels
/
details

Successful Treatment of Advanced Prostate Cancer at American Oncology Institute (AOI) in Hyderabad

NextEdge Admin

31 Jul 2024

3 min 21 sec

The American Oncology Institute,immunotherapy,Oncology

The American Oncology Institute (AOI) at Citizens Specialty Hospital in Hyderabad is pleased to announce the successful treatment of a 72-year-old male patient with advanced prostate cancer. The patient, who initially experienced acute urinary retention in 2014, consulted a urologist and was diagnosed with prostate carcinoma after a biopsy. He underwent bilateral orchidectomy and received multiple lines of chemotherapy at different hospitals, experiencing several relapses.

In 2022, the patient returned to AOI with a recurrence of the disease but surprisingly low PSA levels. The doctors at AOI decided to perform a repeat biopsy, which revealed a transitional cell variant of prostate carcinoma. Considering the patient’s age, frailty, and extensive prior treatments, the medical team conducted next-generation sequencing on the tumor tissue, which showed MSI high and TMB high status, warranting immunotherapy.

Dr. K.V. Krishnamani, Medical Oncologist at AOI, explained the multidisciplinary approach: "The advanced nature of the patient's cancer required a combination of molecular testing and immunotherapy. This comprehensive strategy not only addressed the cancer but also significantly improved the patient's quality of life. His response to the treatment has been very encouraging, showcasing AOI's advanced care capabilities."

The patient received immunotherapy every three weeks, and now, two years from the start of this treatment, his disease is in complete remission. He is clinically well, ambulatory, and in much better health than he was in 2022. This case highlights the necessity of specialized molecular testing, the importance of repeat biopsies in recurrence cases, and the excellent results achievable with immunotherapy in such patients.

Harish Trivedi, CEO of CTSI-South Asia, emphasized the importance of leveraging cutting-edge diagnostics and personalized medicine in cancer treatment. Dr. Prabhakar P, Regional COO of AOI, highlighted AOI's commitment to integrating advanced technology with expert clinical knowledge to provide personalized treatment plans.

Dr. Krishnamani also stressed the importance of regular screenings for early detection of prostate cancer, which significantly improves treatment outcomes. He encourages all men over 50 and those with a family history of the disease to undergo routine check-ups and screenings.